成人H3K27M突变型丘脑胶质瘤患者预后优于未突变患者
该回顾性研究分析了区域中心38例成人丘脑胶质瘤的临床、影像、病理及分子特征,中位无进展生存期7.1个月,中位总生存期15.6个月;20例可检测样本中4例(20%)存在H3K27M突变,突变者生存更长,长期生存者具有年轻、无认知障碍、低剂量类固醇及H3K27M突变特征。
要点
- 成人丘脑胶质瘤中位PFS 7.1个月,中位OS 15.6个月
- 20例分子检测样本中4例(20%)携带H3K27M突变
- H3K27M突变者生存更长,长期生存者年轻、无认知障碍、低类固醇剂量
核心结论
- 成人丘脑胶质瘤在临床、影像和分子特征上与儿童双丘脑胶质瘤不同,年轻、症状有限且伴H3K27M突变者可见长期生存。
- 作者认为需要更大的前瞻性队列来验证这些发现。
研究设计与样本
- 回顾性分析区域中心所有成人丘脑胶质瘤病例的临床、神经影像、组织学和分子特征。
- 共纳入38例成人患者,诊断时中位年龄56.5岁(范围24-80岁),中位KPS 70%。
主要发现
- MRI上三分之二患者存在肿瘤坏死,4例为双丘脑病变,病灶相关强化中位体积较小(14 mm3)。
- 2例接受部分手术切除,其余患者均接受活检。
- 中位PFS为7.1个月(95% CI [3.7-10.5]),中位OS为15.6个月(95% CI [11.7-19.6])。
- 20例有可用肿瘤样本行分子分析的患者中,仅4例(20%)存在H3K27M突变;H3K27M突变患者较未突变者生存更长。
- 长期生存者特征为较年轻、无认知障碍、低剂量类固醇治疗及存在H3K27M突变。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
- 作者在结论中提出需要更大的前瞻性队列来验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adult thalamic gliomas are a rare entity whose management is challenging for physicians. The aim of this study is to describe the characteristics and prognostic factors of thalamic gliomas in adult patients. METHODS: We retrospectively analyzed the clinical, neuro-radiological, histological, and molecular characteristics of all cases of adult thalamic glioma in our regional center. RESULTS: We included 38 adult patients. Median age at diagnosis was 56.5 years old (range, 24-80). Median KPS at diagnosis was 70%. Two-thirds of patients presented with tumor necrosis on MRI. Bithalamic lesions were present in four patients. The median volume of enhancement associated with lesions was relatively small (14 mm3). Two patients had undergone partial surgical resection. All other patients underwent biopsy. Median PFS was 7.1 months (95% CI [3.7-10.5]) and median OS was 15.6 months (95% CI [11.7-19.6]). Among 20 patients with available tumor samples for molecular analyses, only 4 (20%) presented with H3K27M mutation. Patients with H3K27M mutation had longer survival compared to those without. Finally, we identified a long-term survivor population characterized by a younger age, no cognitive impairment, low steroid dose treatment and the presence of H3K27M mutation. CONCLUSION: Thalamic adult glioma differs from bithalamic glioma in children with regards to its clinical, radiological and molecular profiles. Long-term survival is observed in young patients with limited symptoms and H3K27M mutation. A larger prospective cohort is needed to validate these findings.
引用
- Grimaldi S, Harlay V, Appay R, et al. Adult H3K27M mutated thalamic glioma patients display a better prognosis than unmutated patients. J Neurooncol. 2022. PMID: 34994963. doi:10.1007/s11060-022-03943-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。